SG11201401792UA - Fibroblast growth factor 21 variants - Google Patents

Fibroblast growth factor 21 variants

Info

Publication number
SG11201401792UA
SG11201401792UA SG11201401792UA SG11201401792UA SG11201401792UA SG 11201401792U A SG11201401792U A SG 11201401792UA SG 11201401792U A SG11201401792U A SG 11201401792UA SG 11201401792U A SG11201401792U A SG 11201401792UA SG 11201401792U A SG11201401792U A SG 11201401792UA
Authority
SG
Singapore
Prior art keywords
variants
growth factor
fibroblast growth
fibroblast
factor
Prior art date
Application number
SG11201401792UA
Other languages
English (en)
Inventor
Craig Duane Dickinson
David Albert Driver
Ryan James Darling
Malgorzata Donata Gonciarz
Radmila Micanovic
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46964112&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201401792U(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of SG11201401792UA publication Critical patent/SG11201401792UA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/50Fibroblast growth factor [FGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1825Fibroblast growth factor [FGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
SG11201401792UA 2011-10-04 2012-09-25 Fibroblast growth factor 21 variants SG11201401792UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161542906P 2011-10-04 2011-10-04
PCT/US2012/057053 WO2013052311A1 (en) 2011-10-04 2012-09-25 Fibroblast growth factor 21 variants

Publications (1)

Publication Number Publication Date
SG11201401792UA true SG11201401792UA (en) 2014-08-28

Family

ID=46964112

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201401792UA SG11201401792UA (en) 2011-10-04 2012-09-25 Fibroblast growth factor 21 variants

Country Status (27)

Country Link
US (2) US8541369B2 (pl)
EP (1) EP2763689B1 (pl)
JP (1) JP6060167B2 (pl)
KR (1) KR20140059271A (pl)
CN (1) CN103906530B (pl)
AP (1) AP2014007532A0 (pl)
AR (1) AR087973A1 (pl)
AU (1) AU2012318956A1 (pl)
BR (1) BR112014007532A2 (pl)
CA (1) CA2843520A1 (pl)
CL (1) CL2014000801A1 (pl)
CO (1) CO6910165A2 (pl)
CR (1) CR20140142A (pl)
DO (1) DOP2014000050A (pl)
EA (1) EA201490521A1 (pl)
EC (1) ECSP14013285A (pl)
ES (1) ES2548214T3 (pl)
IL (1) IL230754A0 (pl)
IN (1) IN2014CN00782A (pl)
MA (1) MA35458B1 (pl)
MX (1) MX2014004159A (pl)
PE (1) PE20142044A1 (pl)
SG (1) SG11201401792UA (pl)
TN (1) TN2014000096A1 (pl)
TW (1) TWI461435B (pl)
WO (1) WO2013052311A1 (pl)
ZA (1) ZA201400882B (pl)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010523084A (ja) 2007-03-30 2010-07-15 アンブルックス,インコーポレイテッド 修飾fgf−21ポリペプチド
PL2726511T3 (pl) 2011-07-01 2019-12-31 Ngm Biopharmaceuticals, Inc. Kompozycje, zastosowania i sposoby leczenia zaburzeń oraz chorób metabolicznych
SG11201407655TA (en) * 2012-05-15 2014-12-30 Lilly Co Eli Therapeutic uses of fibroblast growth factor 21 proteins
TWI513705B (zh) 2012-06-11 2015-12-21 Lilly Co Eli 纖維母細胞生長因子21蛋白質
KR20150006059A (ko) * 2012-06-11 2015-01-15 일라이 릴리 앤드 캄파니 섬유모세포 성장 인자 21 변이체
NZ630484A (en) 2012-11-28 2017-04-28 Ngm Biopharmaceuticals Inc Compositions and methods for treatment of metabolic disorders and diseases
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
EP2938740B1 (en) 2012-12-27 2022-04-20 NGM Biopharmaceuticals, Inc. Chimeric fgf19 peptides for use in treating bile acid disorders
MX2016004822A (es) 2013-10-28 2016-08-17 Ngm Biopharmaceuticals Inc Modelos de cancer y metodos asociados.
HUE050279T2 (hu) 2014-01-24 2020-11-30 Ngm Biopharmaceuticals Inc Béta-klotho 2-es doménjéhez kötõdõ antitestek és azok alkalmazási módszerei
WO2015138278A1 (en) * 2014-03-11 2015-09-17 Novartis Ag Methods of treating metabolic disorders associated with lipodystrophies and defects in insulin production or signaling
US10398758B2 (en) 2014-05-28 2019-09-03 Ngm Biopharmaceuticals, Inc. Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
EP3155005A4 (en) 2014-06-16 2018-07-11 NGM Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
IL251834B2 (en) 2014-10-23 2023-09-01 Ngm Biopharmaceuticals Inc Pharmaceutical compositions containing peptide variants and methods of using them
TWI705071B (zh) 2014-10-24 2020-09-21 美商必治妥美雅史谷比公司 經修飾之fgf-21多肽及其用途
US10434144B2 (en) 2014-11-07 2019-10-08 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
WO2017019957A2 (en) 2015-07-29 2017-02-02 Ngm Biopharmaceuticals, Inc. Binding proteins and methods of use thereof
ES2871036T3 (es) 2015-11-09 2021-10-28 Ngm Biopharmaceuticals Inc Método para el tratamiento de trastornos relacionados con ácidos biliares
TW201731867A (zh) 2015-12-02 2017-09-16 賽諾菲公司 Fgf21變異體
WO2017220706A1 (en) * 2016-06-22 2017-12-28 Novo Nordisk A/S Pharmaceutical compositions of fgf21 derivatives and uses thereof
WO2018039557A1 (en) 2016-08-26 2018-03-01 Ngm Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors
CN106220724B (zh) * 2016-09-13 2019-10-11 河南师范大学 人成纤维细胞生长因子21重组蛋白及其制备方法和应用
CN106397607A (zh) * 2016-09-13 2017-02-15 河南师范大学 重组人成纤维细胞生长因子21融合蛋白及其在制备治疗代谢疾病药物中的应用
CN106432509B (zh) * 2016-09-13 2019-05-21 河南师范大学 一种治疗代谢疾病的重组人成纤维细胞生长因子21融合蛋白及其制备方法和应用
JP7181886B2 (ja) * 2017-03-14 2022-12-01 サンシャイン・レイク・ファーマ・カンパニー・リミテッド 免疫グロブリンのFc部分を含む二重標的融合タンパク質
SG11202001379WA (en) 2017-09-08 2020-03-30 Bristol Myers Squibb Co Modified fibroblast growth factor 21 (fgf-21) for use in methods for treating nonalcoholic steatohepatitis (nash)
EP3749683A4 (en) * 2018-02-08 2022-03-16 Sunshine Lake Pharma Co., Ltd. FGF21 VARIANT, FUSION PROTEIN AND USE THEREOF
BR112020026512A2 (pt) * 2018-07-03 2021-04-06 Bristol-Myers Squibb Company Formulações de fgf-21
CN109836486B (zh) * 2019-01-30 2020-09-08 北京双因生物科技有限公司 成纤维生长因子21变体、其融合蛋白及其用途
CN114853908B (zh) 2019-05-16 2024-06-07 浙江道尔生物科技有限公司 一种治疗代谢疾病的融合蛋白
MX2022008336A (es) 2020-01-08 2022-08-08 Bristol Myers Squibb Co Formulaciones de conjugados del factor de crecimiento de fibroblastos 21 (fgf-21).
WO2021139744A1 (en) 2020-01-11 2021-07-15 Beijing Ql Biopharmaceutical Co., Ltd. Conjugates of fusion proteins of glp-1 and fgf21
JP2023538533A (ja) 2020-08-07 2023-09-08 ブリストル-マイヤーズ スクイブ カンパニー 線維症の処置のための、ccr2/5拮抗剤と組み合わせたfgf21
KR102495299B1 (ko) * 2020-11-03 2023-02-06 토드제약 주식회사 Fgf21의 열탄력성을 이용한 fgf21 생산 방법
US20240123031A1 (en) 2020-11-25 2024-04-18 Bristol-Myers Squibb Company Methods of treating liver diseases

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
AU2002322394A1 (en) 2001-07-30 2003-02-17 Eli Lilly And Company Method for treating diabetes and obesity
BRPI0416683A (pt) * 2003-12-10 2007-01-30 Lilly Co Eli muteìna de fator de crescimento de fibroblasto de humano 21 (fgf-21), ou um seu peptìdeo biologicamente ativo, polinucleotìdeo, vetor de expressão, célula hospedeira, processo para produzir um polipeptìdeo, composição farmacêutica, método para tratar um paciente, e, uso da muteìna fgf-21
JP4809352B2 (ja) * 2004-09-02 2011-11-09 イーライ リリー アンド カンパニー 線維芽細胞成長因子21の突然変異タンパク質
WO2006028714A1 (en) 2004-09-02 2006-03-16 Eli Lilly And Company Muteins of fibroblast growth factor 21
JP2010523084A (ja) 2007-03-30 2010-07-15 アンブルックス,インコーポレイテッド 修飾fgf−21ポリペプチド
JOP20190083A1 (ar) * 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
WO2010065439A1 (en) * 2008-12-05 2010-06-10 Eli Lilly And Company Variants of fibroblast growth factor 21
US20120052069A1 (en) 2009-05-05 2012-03-01 Amgen Inc Fgf21 mutants and uses thereof
UY32607A (es) 2009-05-05 2010-12-31 Amgen Inc Mutantes de fgf21 y usos del mismo

Also Published As

Publication number Publication date
TWI461435B (zh) 2014-11-21
AP2014007532A0 (en) 2014-03-31
ZA201400882B (en) 2016-02-24
US20130085098A1 (en) 2013-04-04
TW201326198A (zh) 2013-07-01
CR20140142A (es) 2014-05-02
CO6910165A2 (es) 2014-03-31
US8883726B2 (en) 2014-11-11
IN2014CN00782A (pl) 2015-04-03
CA2843520A1 (en) 2013-04-11
IL230754A0 (en) 2014-03-31
AR087973A1 (es) 2014-04-30
BR112014007532A2 (pt) 2017-04-04
CL2014000801A1 (es) 2014-09-12
JP2014530220A (ja) 2014-11-17
EP2763689B1 (en) 2015-08-12
US20130324460A1 (en) 2013-12-05
AU2012318956A1 (en) 2014-02-06
TN2014000096A1 (en) 2015-07-01
CN103906530B (zh) 2016-01-20
ECSP14013285A (es) 2014-05-31
MA35458B1 (fr) 2014-09-01
PE20142044A1 (es) 2014-12-06
JP6060167B2 (ja) 2017-01-11
WO2013052311A1 (en) 2013-04-11
EA201490521A1 (ru) 2014-07-30
KR20140059271A (ko) 2014-05-15
MX2014004159A (es) 2015-02-12
ES2548214T3 (es) 2015-10-14
EP2763689A1 (en) 2014-08-13
US8541369B2 (en) 2013-09-24
CN103906530A (zh) 2014-07-02
DOP2014000050A (es) 2014-04-15

Similar Documents

Publication Publication Date Title
ZA201400882B (en) Fibroblast growth factor 21 variants
ZA201407938B (en) Fibroblast growth factor 21 variants
HK1203357A1 (en) Fibroblast growth factor 21 proteins 21
PL119929U1 (pl) Konewka
GB201322227D0 (en) Watering can
GB201114487D0 (en) Concept 16
GB201114544D0 (en) Concept 25
GB201114530D0 (en) Concept 35
GB201114525D0 (en) Concept 3
GB201114532D0 (en) Concept 36
GB201114523D0 (en) Concept 33
GB201114559D0 (en) Concept 44
GB201114517D0 (en) Concept 15
GB201114480D0 (en) Concept 9
GB201114549D0 (en) Concept 29
GB201114534D0 (en) Concept 37
GB201114535D0 (en) Concept 38
GB201114536D0 (en) Concept 39
GB201114529D0 (en) Concept 34
GB201114545D0 (en) Concept 21
GB201114546D0 (en) Concept 22
GB201114472D0 (en) Concept 14
GB201114478D0 (en) Concept 11
GB201114503D0 (en) Concept 54
GB201114489D0 (en) Concept 12 12